Acalabrutinib (ACP-196) is an orally available, selective irreversible inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. It is a second generation BTK inhibitor with improved pharmacological properties with better plasma exposure, oral absorption and shorter half-life. It prevents the activation of B-cell antigen receptor (BCR) signaling pathway, thus preventing B-cell activation and BTK mediated activation of downstream survival pathways.
Is this a salt?
Is it cell-permeable?
≥98% by HPLC
Maximum time for storage
Protect from air and light
For cells, cell lines and tissues in culture till half confluency.
Acalabrutinib for activation
Acalabrutinib to measure cellular activation
No similar products groups has been found